Drugs.com - New Drug Approvals

Imfinzi Approved in the US as First and Only Immunotherapy Regimen for Patients with Limited-Stage Small Cell Lung Cancer

5 December 2024 -- AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based...

Feb 9, 2025 - 22:25
 0
Imfinzi Approved in the US as First and Only Immunotherapy Regimen for Patients with Limited-Stage Small Cell Lung Cancer
5 December 2024 -- AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based...
Read More

Tags:

Previous Article

FDA Approves Unloxcyt (cosibelimab-ipdl) for the Treatment of Cutaneous Squamous...

Next Article

FDA Grants Accelerated Approval to Bizengri (zenocutuzumab-zbco) for NRG1+ Pancr...

Related Posts

Tevimbra Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

Tevimbra Approved in U.S. for First-line Treatment of G...

Feb 9, 2025  0

FDA Approves Symvess (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

FDA Approves Symvess (acellular tissue engineered vesse...

Feb 9, 2025  0

FDA Approves Gomekli (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

FDA Approves Gomekli (mirdametinib) for the Treatment o...

Feb 12, 2025  0